ClinicalTrials.gg

Program

Gonadotropin-Releasing Hormone

Also written as “GnRH iontophoretic transdermal Lutrepatch”, “Luteinizing Hormone-Releasing Hormone (LHRH) Agonists” and “Lutrepulse”.

Its studies are mostly in Amenorrhea · Infertility · Ovarian Neoplasms, led by 2 companies.

Furthest: phase 3, since Feb 23, 20065 company-led studies, 1 open or runningNext primary completion: Feb 28, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ferring Pharmaceuticals40 open or runningphase 3since Feb 23, 2006Feb 23, 2006none ahead
Hoffmann-La Roche11 open or runningphase 2since Jun 9, 2021Jun 9, 2021Feb 28, 2028phase 2 · NCT04931342

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 23, 2006First study: phase 3 study in InfertilityNew to Ferring PharmaceuticalsFerring Pharmaceuticals · NCT00296465 · 132 enrolled · United States
  2. Nov 20, 2008Phase 2 study in InfertilityFerring Pharmaceuticals · NCT00796289 · 350 enrolled · United States
  3. Oct 15, 2013Phase 3 study in Primary Amenorrhea With Hypogonadotropic HypogonadismFerring Pharmaceuticals · NCT01976728 · 39 enrolled · United States, Canada
  4. Jun 9, 2021Hoffmann-La Roche’s first study: phase 2 study in Ovarian NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT04931342 · 176 enrolled · United States, Australia, Canada and more
  5. Aug 26, 2025Phase 1 study in AmenorrheaFerring Pharmaceuticals · NCT07152730 · United States

Ahead

  1. Feb 28, 2028Primary completion: phase 2 study in Ovarian NeoplasmsHoffmann-La Roche · NCT04931342

TargetBeta

GNRHR →read by rule
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on GNRHR

ProgramCompanyFurthest phaseStudies
LeuprolideruleTakedaphase 439
triptorelinruleIpsenphase 421
GoserelinruleAstraZenecaphase 414
linzagolixruleKissei Pharmaceuticalphase 314
GnRH Antagonist SHR7280Jiangsu HengRui Medicinephase 310
leuprolide mesylateruleforesee-pharmaceuticals-co-ltdphase 33

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07152730Amenorrhea · United States1WithdrawnFerring PharmaceuticalsOct 29, 20250
NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more2Active, not recruitingHoffmann-La RocheFeb 28, 2028176
NCT01976728Primary Amenorrhea With Hypogonadotropic Hypogonadism · United States, Canada3CompletedFerring PharmaceuticalsFeb 23, 201839
NCT00796289Infertility · United States2CompletedFerring PharmaceuticalsDec 2009350
NCT00296465Infertility · United States3CompletedFerring PharmaceuticalsNov 2005132

How it is read

Names in the registry

  • “GnRH iontophoretic transdermal Lutrepatch”, 3 entries
  • “Luteinizing Hormone-Releasing Hormone (LHRH) Agonists”, 1 entry
  • “Lutrepulse”, 1 entry
  • “Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump”, 1 entry
  • “Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.